HK Stock Market Move | XUANZHUBIO-B(02575) rose more than 25% in early trading. New indications for Annilazopine sodium have been approved for Phase III clinical trials.

XUANZHUBIO-B(02575) rose more than 25% in the morning session, as of the deadline, it rose by 20.67% to HK$39.34, with a turnover of HK$533.226 million. On the news side, Xuanzhu Bio announced that the innovative drug developed independently by the group, esomeprazole sodium enteric-coated tablets (trade name: Anjiuwei), recently obtained approval from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration to conduct phase III clinical research on the eradication of Helicobacter pylori with a quadruple therapy containing esomeprazole sodium enteric-coated tablets. The study plans to include 556 Helicobacter pylori-positive adult subjects, with the primary endpoint being the eradication rate of Helicobacter pylori confirmed by the 13C-urea breath test on day 28 after the end of treatment. The approval of this new indication for esomeprazole sodium in phase III clinical trials will help expand the product's indications, enhance the company's influence in the treatment of digestive diseases, and have important implications for the company's long-term development and commercial layout.